A complete cure for HBV

A complete cure for HBV

The opportunity

  • Hepatitis B virus (HBV) infection remains a leading cause of morbidity and mortality worldwide
  • Currently there is no curative treatment regimen 
  • Targeting host cell factors preventing apoptosis of infected cells could lead to a sterilising cure

One third of the world’s population is infected with HBV, either as chronically infected patients (who currently require high-cost life-long treatments) or as HBV carriers without active disease (who currently require life-long clinical monitoring).

HBV causes liver cancer which is responsible for more cancer-related deaths in the world than any other cancer. Presently, there is no cure for HBV infection.


HBV ccle diagram


The technology

We have demonstrated that cellular inhibitor of apoptosis proteins (cIAPs) impair clearance of HBV by preventing TNF-mediated death of infected cells. We have shown that cells infected by HBV (both actively and latently) can be preferentially targeted and cleared using clinical-stage Smac mimetics which antagonise cIAP proteins.

Our mechanistic studies demonstrate that viral clearance requires TNF-α and CD4+T cells.

Scientific diagram


Opportunities for partnership 

We are developing a curative treatment for HBV that targets host cell factors.

We have:

  • A recently published method of treatment patent
  • Preclinical expertise including novel unique model with detection of integrated HBV and cccDNA 
  • Clinical expertise in HBV treatment and management; phase I and II trial design

We are seeking a partner to:

  • Invest in the development of new Smac mimetics in our Drug Discovery Centre 

Scientific team

Professor Marc Pellegrini, Infectious disease physician and Joint Head, Infectious Diseases and Immune Defence division 


Dr Anne-Laure Puaux, Head, Commercialisation

Phone: +61 3 9345 2175 

Email: partnering@wehi.edu.au